Tackle

Tackle Therapeutics is a biotechnology company focused on the discovery and development of next-generation cancer immunotherapies. The company specifically targets the tumor microenvironment (TME) to overcome the mechanisms of immune evasion and suppression that characterize many solid tumors. By modulating the TME, Tackle aims to enhance the recruitment and effector function of immune cells, potentially improving outcomes for patients who do not respond to current checkpoint inhibitors. The company is currently in the pre-clinical stage, leveraging a proprietary approach to identify novel therapeutic targets within the oncology space. Backed by prominent life science venture capital, Tackle is advancing a pipeline of candidates designed to turn immunologically "cold" tumors into "hot" tumors.